ADBICA

ADBICA
Clinical data
ATC code	racemate: none;
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide;
CAS Number	racemate: 1445583-48-1 ;
PubChem CID	racemate: 72710773;
ChemSpider	racemate: 29342130;
UNII	racemate: Q71G788A6H; S isomer: P0248QCZ04 ;
CompTox Dashboard (EPA)	racemate: DTXSID801009996 ;
Chemical and physical data
Formula	C20H29N3O2
Molar mass	343.471 g·mol−1
3D model (JSmol)	racemate: Interactive image; S isomer: Interactive image;
	SMILES racemate: CCCCCN1C=C(C2=CC=CC=C21)C(=O)NC(C(=O)N)C(C)(C)C; ; S isomer: CCCCCN1C=C(C2=CC=CC=C21)C(=O)N[C@H](C(=O)N)C(C)(C)C;
	InChI racemate: InChI=1S/C20H29N3O2/c1-5-6-9-12-23-13-15(14-10-7-8-11-16(14)23)19(25)22-17(18(21)24)20(2,3)4/h7-8,10-11,13,17H,5-6,9,12H2,1-4H3,(H2,21,24)(H,22,25); Key:IXUYMXAKKYWKRG-UHFFFAOYSA-N;

ADBICA (also known as ADB-PICA) is a designer drug identified in synthetic cannabis blends in Japan in 2013.^[1] ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like SDB-001 and STS-135. The stereochemistry of the tert-butyl side-chain in the product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers.^[2] ADBICA is a potent agonist of the CB₁ receptor and CB₂ receptor with an EC₅₀ value of 0.69 nM and 1.8 nM respectively.^[3]